Infinimmune
Develops antibody drugs using a human-centered discovery approach to identify and advance better therapeutic candidates.
Overview
Infinimmune develops antibody drugs with what it describes as a more human approach to therapeutic discovery. The company targets the healthcare and biopharma market, focusing on improving how antibody drug candidates are identified and developed. The company’s stated differentiator is its human-centered method for developing better antibody medicines. Infinimmune raised $75 million in a Series A round announced on August 11, 2026, representing its disclosed total funding to date.
Funding History
Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs
Frequently Asked Questions
- How much funding does AI Funding track for Infinimmune?
- AI Funding tracks $75M for Infinimmune across 1 funding round in this database.
- What does Infinimmune do?
- Infinimmune develops antibody drugs with what it describes as a more human approach to therapeutic discovery. The company targets the healthcare and biopharma market, focusing on improving how antibody drug candidates are identified and developed. The company’s stated differentiator is its human-centered method for developing better antibody medicines. Infinimmune raised $75 million in a Series A round announced on August 11, 2026, representing its disclosed total funding to date.
- Where is Infinimmune headquartered?
- Infinimmune is headquartered in San Francisco, United States.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.